We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 0A9G market cap is 0. The company's latest EPS is GBP -0.0473 and P/E is -60.89.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Revenue | 2.56M | 0 | 36.46M | 811k | 8.04M |
| Operating Income | -36.96M | -37.57M | -20.94M | -42.76M | -32.84M |
| Net Income | -34.84M | -163.63M | 12.73M | -33.24M | -33.18M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Total Assets | 86.45M | 62.95M | 126.42M | 84.12M | 62.5M |
| Total Liabilities | 46.19M | 77.92M | 38.42M | 21.58M | 13.19M |
| Total Equity | 40.26M | -14.97M | 88M | 62.54M | 49.31M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| GBP (£) | GBP (£) | GBP (£) | GBP (£) | GBP (£) | |
| Operating | -45.93M | -28.34M | -5.24M | -38.82M | -17.63M |
| Investing | 43.3M | 1.5M | -421k | 1.5M | 1.29M |
| Financing | -5.71M | 34.74M | 77.65M | -784k | 5.09M |
| Market Cap | 0 |
| Price to Earnings Ratio | -60.89 |
| Price to Sales Ratio | 250.43 |
| Price to Cash Ratio | 44.79 |
| Price to Book Ratio | 40.96 |
| Dividend Yield | - |
| Shares Outstanding | 701.22M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Mereo Biopharma Group Plc |
| Address |
fourth floor london W1G 0QF |
| Website | https://www.mereobiopharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
